The author discusses the key issues to consider when using isolators such as containment, protection of personnel, the efficiency of biodecontamination cycles, sterility assurance levels, barriers and their integrity, and environmental impact.
Maurizio Battistini
Advertisement
Maurizio Battistini is the general manager of APP Pharmaceutical Partners in Switzerland.
Articles by Maurizio Battistini
A comparison of conventional cleanrooms, restricted access barrier systems, and isolators, shows the benefits of using isolators in high-potency drug manufacturing.
Risk management is essential in any successful outsourcing partnership. The author outlines the steps toward identifying, understanding, and controlling risk in key manufacturing areas.
Advertisement
Latest Updated Articles
Manufacturing High-Potency Drugs Using IsolatorsPublished: November 1st 2008 | Updated:
- Comparison of Conventional Cleanrooms, Restricted Access Barrier Systems, and Isolators
Published: November 1st 2008 | Updated:
The Role of Risk Analysis in Expanding Business ActivitiesPublished: August 1st 2007 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Implications on SMA Care of High-Dose Nusinersen
2
Shifting from Trial-and-Error to Rational Design Drives Efficiency in Pharmaceutical Formulation
3
Nuclear Waste to Medicine: The UK’s Lead-212 Strategy for Cancer Care
4
New Targets for Clinical Trials in the European Union
5
